Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti–transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Neuropathic pain is a major unmet medical need, with only 30% to 35% of patients responding to the current standard of care. The discovery and development of novel therapeutics to address this unmet need have been hampered by poor target engagement, the selectivity of novel molecules, and limited access to the relevant compartments. Biological therapeutics, either monoclonal antibodies (mAbs) or peptides, offer a solution to the challenge of specificity as the intrinsic selectivity of these kinds of molecules is significantly higher than traditional medicinal chemistry–derived approaches. The interleukin-1 receptor system within the spinal cord has been implicated in the amplification of pain signals, and its central antagonism provides relief of neuropathic pain. Targeting the IL-1 system in the spinal cord with biological drugs, however, raises the even greater challenge of delivery to the central compartment. Targeting the transferrin receptor with monoclonal antibodies has proved successful in traversing the endothelial cell–derived blood–brain barrier and delivering proteins to the central nervous system. In this study, we describe a novel construct exemplifying an engineered solution to overcome these challenges. We have generated a novel anti–transferrin receptor-interleukin-1 receptor antagonist fusion that transports to the central nervous system and delivers efficacy in a model of nerve ligation–induced hypersensitivity. Approaches such as these provide promise for novel and selective analgesics that target the central compartment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seltzer, Z., Dubner, R., & Shir, Y. (1990) · Pain · doi:10.1016/0304-3959(90)91074-s · Cited by 1,847
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Kawasaki, Y., Zhang, L., Cheng, J.-K., & Ji, R.-R. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3338-07.2008 · Cited by 1,162 · cited 1×
“In the CNS, IL-1 induces COX-2 expression, contributing to central hyperexcitability,(32) and increases synaptic activity in superficial spinal cord.(17) Sponsorships or competing interests that may be relevant to content are disclosed”
BackgroundBoosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622
Carter, D. B., Deibel, M. R., Dunn, C. J., Tomich, C.-S. C., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., et al. (1990) · Nature · doi:10.1038/344633a0 · Cited by 601
Daramola, O., Stevenson, J., Dean, G., Hatton, D., Pettman, G., Holmes, W., & Field, R. (2014) · Biotechnology Progress · doi:10.1002/btpr.1809 · Cited by 134 · cited 1×
“Antibodies were expressed in transiently transfected Chinese hamster ovary cells in serum-free media as described previously.(10) Cultures were maintained in a humidified incubator at 37 ̊C, 5%CO2 for 14 days after which the medium was harvested.”
Method
Cited by
Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482
Targeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 370
Kariolis, M. S., Wells, R. C., Getz, J. A., Kwan, W., Mahon, C. S., Tong, R., Kim, D. J., Srivastava, A., Bedard, C., Henne, K. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1359 · Cited by 349
Boakye, P. A., Tang, S.-J., & Smith, P. A. (2021) · Frontiers in Pain Research · doi:10.3389/fpain.2021.698157 · Cited by 102
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Metadata
- Authors
- Webster, C. I., Hatcher, J., Burrell, M., Thom, G., Thornton, P., Gurrell, I., & Chessell, I.
- Venue
- Pain
- Published
- 2016-12-20
- Volume
- 158
- Issue
- 4
- Pages
- 660-668
- ISSN
- 0304-3959 (ISSN-L)
- 1872-6623
- OpenAlex
- W2566127747
- Cited by
- 63
- References
- 7
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti–transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity. https://app.cochat.ai/papers/10.1097/j.pain.0000000000000810
- The paper
- Webster, C. I., Hatcher, J., Burrell, M., Thom, G., Thornton, P., Gurrell, I., & Chessell, I. (2017). Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti–transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity. Pain. https://doi.org/10.1097/j.pain.0000000000000810
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.